Breaking News Instant updates and real-time market news.

OMER

Omeros

$14.67

1.29 (9.64%)

09:11
04/12/18
04/12
09:11
04/12/18
09:11

Omeros says OMIDRIA added to Veterans Health Administration National Formulary

Omeros announced that the Veterans Administration has added OMIDRIA to the VA National Formulary. The VA National Formulary is a listing of drugs and supplies that must be available at all VA facilities for the benefit of U.S. military veterans. Omeros' commercial drug OMIDRIA is the first and only FDA-approved product to maintain pupil size by preventing intraoperative miosis and to reduce postoperative pain associated with cataract or lens replacement surgery. It is estimated that approximately 65,000 to 80,000 cataract surgery procedures will be performed in the VA system in 2018. Over 90 percent of all U.S. medical schools are affiliated with a VA facility. The VA conducts the largest education and training effort for health professionals in the nation with nearly all U.S.-trained physicians receiving some or all of their training in the VA system. The decision to add OMIDRIA to the VA formulary was made following review of the expanding set of efficacy and safety data for OMIDRIA, including publications in peer-reviewed journals documenting a number of the drug's clinical benefits such as fewer surgical complications, reduced need for iris-damaging pupil-expansion devices, less postoperative pain and better surgical outcomes.

  • 16

    Apr

  • 17

    Apr

  • 18

    Apr

  • 25

    Apr

OMER Omeros
$14.67

1.29 (9.64%)

03/02/18
NEED
03/02/18
DOWNGRADE
NEED
Hold
Needham downgrades Omeros amid 'plummeting' Omidria sales
Needham analyst Serge Belanger downgraded Omeros to Hold from Buy saying there is no visibility on a near-term resolution to Omidria's reimbursement status or when sales will resume at a "meaningful level." He sees an uncertain future for the drug without reimbursement and notes its sales are "plummeting." It is now unclear if Omeros has the resources to advance OMS721 development programs without Omidria revenue contributing to the funding, Belanger tells investors in a research note. Omeros in midday trading is down 8% to $9.01 following last night's Q4 results.
03/22/18
MAXM
03/22/18
NO CHANGE
Target $25
MAXM
Buy
Omeros short-term reimbursement overhang removal 'great news,' says Maxim
Maxim analyst Jason McCarthy said Omeros resolution of of reimbursement "pass through" status removes an overhang. McCarthy expects Omidria to return to its previous trend of growing sales, and raised his estimates for 2018 to account for the news, while increasing his price target to $25 from $24 and reiterating a Buy rating on Omeros shares
03/23/18
WEDB
03/23/18
DOWNGRADE
Target $19
WEDB
Neutral
Omeros downgraded to Neutral from Outperform at Wedbush
Wedbush analyst Liana Moussatos downgraded Omeros to Neutral and lowered her price target for the shares to $19 from $47. The analyst sees a "lack of clarity for the financial status" with disruption in Omidria sales and the company's inability to fund progress with its top potential value driver OMS721. Even with possible extension of Omidria pass-through reimbursement for two additional years starting in October 2018, sales are unlikely to fund the pipeline in 2018 and 2019, Moussatos tells investors in a research note. Omeros closed yesterday up 35%, or $4.11, to $15.75.
03/23/18
HCWC
03/23/18
NO CHANGE
Target $34
HCWC
Buy
Omeros price target raised to $34 from $30 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Omeros to $34 after Omidria pass-through reimbursement status was extended. The language in the spending bill provides the extension for a period of two years, Selvaraju tells investors in a research note. This is an "unexpected success" for Omeros, and should lead to a "significant rebound" in Omidria sales and resumption of growth in the franchise, Selvaraju writes. He reiterates a Buy rating on Omeros shares.

TODAY'S FREE FLY STORIES

16:15
08/16/18
08/16
16:15
08/16/18
16:15
General news
Breaking General news story  »

Week of 8/15 Fed Balance…

16:15
08/16/18
08/16
16:15
08/16/18
16:15
General news
Breaking General news story  »

Week of 8/6 Money Supply…

TSLA

Tesla

$335.46

-3.2 (-0.94%)

16:14
08/16/18
08/16
16:14
08/16/18
16:14
Periodicals
SEC presses Tesla directors for info on communications with Musk, WSJ says »

Federal regulators are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

MRK

Merck

$68.85

1.49 (2.21%)

, ESALY

Eisai

$0.00

(0.00%)

16:14
08/16/18
08/16
16:14
08/16/18
16:14
Hot Stocks
Merck, Eisai announce FDA approval of LENVIMA capsules »

Eisai Inc. (ESALY) and…

MRK

Merck

$68.85

1.49 (2.21%)

ESALY

Eisai

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 24

    Aug

  • 10

    Sep

  • 12

    Sep

  • 03

    Oct

  • 23

    Oct

  • 29

    Oct

  • 16

    Feb

ATGE

Adtalem Global Education

$55.60

-0.4 (-0.71%)

16:13
08/16/18
08/16
16:13
08/16/18
16:13
Earnings
Breaking Earnings news story on Adtalem Global Education »

Adtalem Global Education…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

ARAY

Accuray

$3.50

0.05 (1.45%)

16:12
08/16/18
08/16
16:12
08/16/18
16:12
Hot Stocks
Accuray CFO Kevin Waters departing October 1, interim CFO appointed »

Accuray CFO Kevin Waters…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

HDSN

Hudson Technologies

$1.76

-0.07 (-3.83%)

16:12
08/16/18
08/16
16:12
08/16/18
16:12
Hot Stocks
Hudson Technologies receives deficiency letter from Nasdaq »

Hudson Technologie…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATGE

Adtalem Global Education

$55.65

-0.35 (-0.63%)

16:11
08/16/18
08/16
16:11
08/16/18
16:11
Earnings
Adtalem Global Education reports Q4 continuing operations EPS 86c, consensus 91c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

ARAY

Accuray

$3.50

0.05 (1.45%)

16:11
08/16/18
08/16
16:11
08/16/18
16:11
Earnings
Accuray sees FY19 revenue $415M-$425M, consensus $398.38M »

Sees adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

AMAT

Applied Materials

$47.19

-0.3 (-0.63%)

16:11
08/16/18
08/16
16:11
08/16/18
16:11
Hot Stocks
Breaking Hot Stocks news story on Applied Materials »

Applied Materials reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

ATAI

ATA Inc.

$6.80

0.06 (0.89%)

16:09
08/16/18
08/16
16:09
08/16/18
16:09
Hot Stocks
ATA Inc. to acquire Beijing Biztour »

ATA Inc announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAT

Mattel

$15.17

-0.11 (-0.72%)

16:08
08/16/18
08/16
16:08
08/16/18
16:08
Hot Stocks
Mattel names Steve Totzke as Chief Commercial Officer »

Mattel announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMAT

Applied Materials

$47.25

-0.24 (-0.51%)

16:08
08/16/18
08/16
16:08
08/16/18
16:08
Hot Stocks
Breaking Hot Stocks news story on Applied Materials »

Applied Materials down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

JWN

Nordstrom

$52.11

0.25 (0.48%)

16:08
08/16/18
08/16
16:08
08/16/18
16:08
Earnings
Nordstrom raises FY18 EPS view to $3.50-$3.65 from $3.35-$3.55 »

Consensus $3.46. Raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

PFNX

Pfenex

$4.77

0.07 (1.49%)

16:08
08/16/18
08/16
16:08
08/16/18
16:08
Hot Stocks
Pfenex CMO Dr. Hubert Chen resigns »

Pfenex announced that Dr.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARAY

Accuray

$3.50

0.05 (1.45%)

16:07
08/16/18
08/16
16:07
08/16/18
16:07
Earnings
Accuray reports Q4 EPS (1c), consensus (2c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

ICFI

ICF International

$80.65

1.15 (1.45%)

16:07
08/16/18
08/16
16:07
08/16/18
16:07
Hot Stocks
ICF International awarded $20M task order from DHIS »

ICF was recently awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZOES

Zoe's Kitchen

$9.48

(0.00%)

16:07
08/16/18
08/16
16:07
08/16/18
16:07
Hot Stocks
Zoe's Kitchen postpones earnings release, conference call until August 17 »

Zoe's Kitchen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

JWN

Nordstrom

$52.13

0.27 (0.52%)

16:06
08/16/18
08/16
16:06
08/16/18
16:06
Earnings
Nordstrom reports Q2 EPS 95c, consensus 84c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

AMAT

Applied Materials

$47.26

-0.23 (-0.48%)

16:06
08/16/18
08/16
16:06
08/16/18
16:06
Earnings
Applied Materials sees FY18 EPS $4.41-$4.49, consensus $4.59 »

Sees FY18 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

EDIT

Editas Medicine

$29.80

0.7 (2.41%)

16:05
08/16/18
08/16
16:05
08/16/18
16:05
Hot Stocks
Editas Medicine announces completion of recombinant DNA committee registration »

Editas Medicine announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

ESRX

Express Scripts

$87.21

0.52 (0.60%)

, CI

Cigna

$187.93

2.48 (1.34%)

16:05
08/16/18
08/16
16:05
08/16/18
16:05
Hot Stocks
Express Scripts urges stockholders to vote in favor of merger with Cigna »

Express Scripts (ESRX)…

ESRX

Express Scripts

$87.21

0.52 (0.60%)

CI

Cigna

$187.93

2.48 (1.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

  • 24

    Aug

  • 12

    Sep

AMAT

Applied Materials

$47.39

-0.105 (-0.22%)

16:04
08/16/18
08/16
16:04
08/16/18
16:04
Earnings
Applied Materials sees Q4 EPS 92c-$1.00, consensus $1.17 »

Sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

AMAT

Applied Materials

$47.39

-0.105 (-0.22%)

16:04
08/16/18
08/16
16:04
08/16/18
16:04
Hot Stocks
Applied Materials CEO says FY18 to deliver double digit grown in all groups »

"While we have seen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

OVID

Ovid Therapeutics

$6.46

-0.095 (-1.45%)

16:03
08/16/18
08/16
16:03
08/16/18
16:03
Hot Stocks
Ovid Therapeutics announces Phase 2 STARS topline data accepted for presentation »

Ovid Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.